SNY
Sanofi
NASDAQ · Healthcare · Drug Manufacturers - General · FR
$44.24
−0.20%Aug 17, 2026, 19:23 UTC
Sanofi will lay off 229 workers in Massachusetts, affecting employees of Blueprint Medicines, which Sanofi acquired in a $9.1 billion deal in July 2025.
Source:Aug 9, 2026, 23:16 UTC
Sanofi alerted patient groups and physicians in the U.S. and Europe that supplies of Myozyme and Nexviazyme are dwindling due to a bottleneck in the final manufacturing phase and quality control issues at its Waterford plant.
Source:Aug 4, 2026, 11:00 UTC
Nurix Therapeutics earned a $10 million milestone payment after collaborator Sanofi initiated a Phase 1 clinical trial of the oral STAT6 degrader SAR448272/NX-3911 for type 2 inflammatory diseases.
Source:Aug 4, 2026, 05:00 UTC
The European Commission approved Sanofi's MenQuadfi vaccine for use in infants from six weeks of age against invasive meningococcal disease.
Source:Jul 30, 2026, 17:06 UTC
Sanofi reported Q2 2026 earnings and sales that beat expectations, with Dupixent quarterly sales exceeding 5 billion euros for the first time.
Source:Jul 24, 2026, 16:15 UTC
The African Development Bank finalized a loan of up to $15 million to Biovac to support a new multi-vaccine manufacturing facility in Cape Town.
Jul 24, 2026, 11:53 UTC
Japan's parliament passed a revised Vaccination Act that treats antibody preparations as equivalent to vaccines, enabling public funding for RS virus preventive treatment.
Source:Jul 24, 2026, 05:30 UTC
Sanofi announced discontinuation of clinical development of amlitelimab in moderate-to-severe atopic dermatitis.
Jul 23, 2026, 16:23 UTC
Sanofi's Lantus Solostar insulin pen is experiencing supply shortages due to increased demand, and the company is accelerating production to address the issue.
Source:Jul 21, 2026, 16:00 UTC
Sanofi announced an evolution of its Executive Committee to support its next strategic chapter.
Source:Jul 21, 2026, 11:03 UTC
Sanofi's Japanese subsidiary announced a delay in the launch of its high-dose influenza vaccine 'Efluelda' for older adults, originally planned for autumn 2026.
Source:Jul 17, 2026, 10:30 UTC
Aqemia and Sanofi expanded their research collaboration, nominating a new therapeutic target and making an additional payment.
Source:Jul 13, 2026, 20:01 UTC
Paulo Fontoura resigned from the Board of Directors of Lakefront Biotherapeutics NV after being appointed Global Head of R&D at Sanofi SA.
Jul 10, 2026, 12:35 UTC
The US FDA approved Sanofi's subcutaneous Sarclisa Escena as the first anticancer treatment administered via an on-body injector.
Source:Jul 8, 2026, 10:00 UTC
The European Commission seeks feedback on commitments offered by Sanofi to address suspected anti-competitive behaviour in a flu vaccine marketing campaign.
Source:Jul 2, 2026, 10:46 UTC
Sanofi inaugurated its first China Innovation and Operations Center in Chengdu, which was officially established in March 2026.
Source:Jun 30, 2026, 05:44 UTC
Sanofi's Nexviazyme drug met primary and secondary goals in a late-stage clinical trial for the most aggressive variant of Pompe disease in infants.
Source:Jun 26, 2026, 10:47 UTC
The European Commission launched an antitrust probe into French drugmaker Sanofi over alleged misleading communications against rival flu vaccine Fluad.
Jun 23, 2026, 05:15 UTC
Japan's Ministry of Health, Labour and Welfare granted marketing and manufacturing authorization to Sanofi's Wayrilz for the treatment of immune thrombocytopenia.
Source:Jun 22, 2026, 14:22 UTC
Bionyra Pharma launched and raised €143 million in an oversubscribed Series A financing round co-led by Jeito Capital and Sofinnova Partners, with participation from Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures.
Source:Jun 19, 2026, 10:31 UTC
Japan's Ministry of Health, Labour and Welfare approved Sanofi's Sarclisa subcutaneous formulation for multiple myeloma.
Source:Jun 18, 2026, 12:00 UTC
COUR Pharma closed a $50 million Series B financing round led by Lumira Ventures and Roche Venture Fund with new investment from Sanofi.
Source:Jun 15, 2026, 17:15 UTC
Sanofi received FDA approval to expand the use of Tzield in children with newly diagnosed stage 3 type 1 diabetes.
Source:Jun 13, 2026, 13:22 UTC
The FDA approved teplizumab, a type 1 diabetes drug developed by Sanofi, for children aged 8 and older with stage 3 diabetes.
Source:Jun 12, 2026, 22:09 UTC
Sanofi's Tzield received US approval as the first disease-modifying therapy for recently diagnosed stage 3 type 1 diabetes patients.
Source:Jun 10, 2026, 15:51 UTC
Kymera Therapeutics starts patient dosing in a phase I study of KT-485 for hidradenitis suppurativa, triggering a $20 million milestone payment from Sanofi.
Source:Jun 10, 2026, 14:31 UTC
Sanofi halted a Phase 3 study of its drug riliprubart after an interim analysis showed the therapy was not effective.
Jun 8, 2026, 17:41 UTC
Sanofi received European Union approval for a subcutaneous formulation of Sarclisa for the treatment of multiple myeloma.
Source:
Page 1Next →